

Ad hoc announcement



CytoTools

Ad hoc announcement in accordance with Art. 17 of the European Market Abuse Directive

CytoTools AG: First in-house development of a German biotechnology company receives production approval and marketing authorization in India

Darmstadt, 31st October 2019 – The wound healing drug DermaPro® from the CytoTools subsidiary DermaTools Biotech GmbH has received market approval in India for the diabetic foot indication. The DermaTools GmbH reports that Centaur Pharmaceuticals Pvt. Ltd., Mumbai, the Indian licensee and cooperation partner, has been granted approval by the Indian drug regulation authorities (Drug Controller General of India) for the production of the active substance molecule DPOCL, and to produce and market the final application formulation. Thus, for the first time, the DermaTools company has obtained an approval for its new, worldwide-patented active substance molecule. With this final approval, the Indian health authorities recognize the superior performance properties of our new drug in comparison with the previous standard therapy.

The preparations for the market launch in India now commence with this marketing approval. There, the active substance will be placed on the market under the name Woxheal® by Centaur Pharmaceuticals. The CytoTools AG will receive corresponding license fees.

End of the ad hoc announcement

Contact:

CytoTools AG

Dr. Mark Andre Freyberg

CEO

Klappacher Str. 126

D-64285 Darmstadt

Tel.: +49-6151-95158-12

Fax: +49-6151-95158-13

E-Mail: freyberg@cytotools.de

Ad hoc announcement



CytoTools

Ingo Janssen
Haus der Wirtschaft
Kapstadtring 10
D-22297 Hamburg
Tel.: +49-40-6378-5410
Fax: +49-40 6378-5423
E-Mail: ir@ubj.de

About CytoTools

CytoTools AG is a German biotechnology company focused on translating the results of fundamental biology research on the mechanisms of cell growth and programmed cell death into novel therapies, that are designed to treat the cause of the disease rather than the symptoms. The company has developed a robust and diverse pipeline of self-developed chemical compounds and biopharmaceuticals with the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (62 %) and CytoPharma GmbH (50%).